# Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.

> **NCT04348695** · PHASE2 · COMPLETED · sponsor: **Fundación de investigación HM** · enrollment: 94 (actual)

## Conditions studied

- Coronavirus Infection

## Interventions

- **DRUG:** Ruxolitinib plus simvastatin
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT04348695
- **Lead sponsor:** Fundación de investigación HM
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-12
- **Primary completion:** 2021-01-31
- **Final completion:** 2021-01-31
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2022-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04348695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04348695, "Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04348695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*